Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-09-2019 | Paget's Disease of Bone | Original Article – Cancer Research

The vulvar immunohistochemical panel (VIP) project: molecular profiles of vulvar Paget’s disease

Authors: Giorgia Garganese, Frediano Inzani, Giulia Mantovani, Angela Santoro, Michele Valente, Gabriele Babini, Giuliana Petruzzellis, Simona Maria Fragomeni, Stefano Gentileschi, Sonia Bove, Massimo Franchi, Giuseppe Angelico, Anna Fagotti, Giovanni Scambia, Gian Franco Zannoni

Published in: Journal of Cancer Research and Clinical Oncology | Issue 9/2019

Abstract

Purpose

To investigate the expression of biological markers in primary vulvar Paget’s disease (VPD).

Methods

Forty-one patients referred to a single major Center for Gynecologic Oncology from January 2008 to June 2018 were enrolled retrospectively: 30 non-invasive-VPD and 11 invasive-VPD. A total number of 60 samples, from all the 41 vulvar sites (VS), 8 metastatic lymph node sites (MLS) and 11 successive recurrent disease in vulvar site (RVS), were tested for an immunohistochemical panel, including the following markers: PD-L1, CD3, MSH2, MSH6, MLH1, PMS2, HER2/neu, EGFR, p16, p53, Ki67, ER, PR, AR, VEGF and CD31.

Results

We found a positive PD-L1 in 10% of non-invasive-VPD and 27% of invasive-VPD (18% VS; 38% MLS). ER and AR were expressed respectively in more than 70% and 75% of all specimens. HER2/neu amplification was found in 21% of non-invasive-VPD and 45% of invasive-VPD (40% VS; 38% MLS). A machine learning cluster analysis identified three groups among non- invasive-VPD: cluster-1 with higher median ER expression (40%); cluster-3 with more frequent HER2/neu overexpression (46%). Among invasive-VPD, two clusters were found: the second with more frequent HER2/neu overexpression (67% vs. 0%) and nodal metastases (100% vs. 25%). Repeating the IHC panel on the correspondent MLS and RVS, it significantly changed, respectively, in 50% and 27%.

Conclusions

This study reveals the expression of PDL-1 and ER and confirms the expression of HER2/AR in VPD; new bases are provided to design multicenter clinical trials on personalized target therapies.

Alessandrini L, Clemente N, Perin T, Giorda G, Canzonieri V, Sopracordevole F (2018) Extramammary Paget disease of the vulva: immunohistochemical analysis of neoangiogenesis and epithelial-mesenchymal transition markers expression. Diagn Pathol 13(1):2CrossRefPubMedPubMedCentral

Al-Obaidy KI, Kao C-S, Idrees MT (2018) P16 expression in extramammary Paget’s disease of the vulva and scrotum is not human papillomavirus related. Int J Surg Pathol 1:1066896918775513

Azmahani A, Nakamura Y, Ozawa Y, McNamara KM, Fujimura T, Haga T et al (2015) Androgen receptor, androgen-producing enzymes and their transcription factors in extramammary Paget disease. Hum Pathol 46(11):1662–1669CrossRefPubMed

Chen S-Y, Takeuchi S, Moroi Y, Hayashida S, Kido M, Uchi H et al (2008) Concordant over-expression of transcription factor Sp1 and vascular endothelial growth factor in extramammary Paget’s disease. Int J Dermatol 47(6):562–566CrossRefPubMed

Diaz de Leon E, Carcangiu ML, Prieto VG, McCue PA, Burchette JL, To G et al (2000) Extramammary Paget disease is characterized by the consistent lack of estrogen and progesterone receptors but frequently expresses androgen receptor. Am J Clin Pathol 113(4):572–575CrossRefPubMed

Edey KA, Allan E, Murdoch JB, Cooper S, Bryant A (2013) Interventions for the treatment of Paget’s disease of the vulva. Cochrane Database Syst Rev 26(10):CD009245

Ellis PE, Fong LFWT, Rolfe KJ, Crow JC, Reid WMN, Davidson T et al (2002a) The role of p53 and Ki67 in Paget’s disease of the vulva and the breast. Gynecol Oncol 86(2):150–156CrossRefPubMed

Ellis PE, Wong Te Fong LF, Rolfe KJ, Crow JC, Reid WMN, Davidson T et al (2002b) The role of vascular endothelial growth factor-A (VEGF-A) and platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) in Paget’s disease of the vulva and breast. Anticancer Re 22(2A):857–861

Ellis PE, MacLean AB, Wong Te Fong LF, Crow JC, Perrett CW (2012) Angiogenesis in Paget’s disease of the Vulva and the Breast: correlation with microvessel density. J Oncol [Internet] Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3321467/

Fujimoto A, Takata M, Hatta N, Takehara K (2000) Expression of structurally unaltered androgen receptor in extramammary Paget’s disease. Lab Investig J Tech Methods Pathol 80(9):1465–1471CrossRef

Garganese G, Collarino A, Fragomeni SM, Rufini V, Perotti G, Gentileschi S et al (2017) Groin sentinel node biopsy and 18F-FDG PET/CT-supported preoperative lymph node assessment in cN0 patients with vulvar cancer currently unfit for minimally invasive inguinal surgery: the GroSNaPET study. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 43(9):1776–1783

Gentileschi S, Servillo M, Garganese G, Fragomeni S, De Bonis F, Scambia G et al (2016) Surgical therapy of vulvar cancer: how to choose the correct reconstruction? J Gynecol Oncol. 27(6):e60CrossRefPubMedPubMedCentral

Gentileschi S, Servillo M, Garganese G, Fragomeni S, De Bonis F, Cina A et al (2017) The lymphatic superficial circumflex iliac vessels deep branch perforator flap: a new preventive approach to lower limb lymphedema after groin dissection-preliminary evidence. Microsurgery 37(6):564–573CrossRefPubMed

Hirakawa S, Detmar M, Kerjaschki D, Nagamatsu S, Matsuo K, Tanemura A et al (2009) Nodal lymphangiogenesis and metastasis: role of tumor-induced lymphatic vessel activation in extramammary Paget’s disease. Am J Pathol 175(5):2235–2248CrossRefPubMedPubMedCentral

Hummel M, Edelmann D, Kopp-Schneider A (2017) Clustering of samples and variables with mixed-type data. PLoS One [Internet] 12(11). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705083/

Inoguchi N, Matsumura Y, Kanazawa N, Morita K, Tachibana T, Sakurai T et al (2007) Expression of prostate-specific antigen and androgen receptor in extramammary Paget’s disease and carcinoma. Clin Exp Dermatol 32(1):91–94PubMed

Kang Z, Xu F, Zhu Y, Fu P, Zhang Q-A, Hu T et al (2016) Genetic analysis of mismatch repair genes alterations in extramammary Paget disease. Am J Surg Pathol 40(11):1517–1525CrossRefPubMed

Karam A, Berek JS, Stenson A, Rao J, Dorigo O (2008) HER-2/neu targeting for recurrent vulvar Paget’s disease. A case report and literature review. Gynecol Oncol 111(3):568–571CrossRefPubMed

Larbouret C, Gaborit N, Chardès T, Coelho M, Campigna E, Bascoul-Mollevi C et al (2012) In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors’ down-regulation and dimers’ disruption. Neoplasia 14(2):121–130CrossRefPubMedPubMedCentral

Liegl B, Horn L-C, Moinfar F (2005) Androgen receptors are frequently expressed in mammary and extramammary Paget’s disease. Mod Pathol Off J U S Can Acad Pathol Inc 18(10):1283–1288

Mantovani G, Fagotti A, Franchi M, Scambia G, Garganese G (2019) Reviewing vulvar Paget’s disease molecular bases. Looking forward to personalized target therapies: a matter of CHANGE. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 29:422–429CrossRef

Tagliaferri L, Casà C, Macchia G, Pesce A, Garganese G, Gui B et al (2018) The role of radiotherapy in extramammary Paget disease: a systematic review. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 28(4):829–839CrossRef

Teng MWL, Ngiow SF, Ribas A, Smyth MJ (2015) Classifying cancers based on T cell Infiltration and PD-L1. Cancer Res 75(11):2139–2145CrossRefPubMedPubMedCentral

van der Linden M, Meeuwis KAP, Bulten J, Bosse T, van Poelgeest MIE, de Hullu JA (2016) Paget disease of the vulva. Crit Rev Oncol Hematol 101:60–70CrossRefPubMed

Van der Zee AGJ, Oonk MH, De Hullu JA, Ansink AC, Vergote I, Verheijen RH et al (2008) Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol Off J Am Soc Clin Oncol. 26(6):884–889CrossRef

Wilkinson EJ, Brown HM (2002) Vulvar Paget disease of urothelial origin: a report of three cases and a proposed classification of vulvar Paget disease. Hum Pathol 33(5):549–554CrossRefPubMed

Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: american Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol 31(31):3997–4013CrossRef

Xu X, Shao N, Qiao D, Wang Z, Song N, Song N (2015) Expression of vascular endothelial growth factor and basic fibroblast growth factor in extramammary Paget disease. Int J Clin Exp Pathol 8(3):3062–3068PubMedPubMedCentral

Zhang C, Zhang P, Sung CJ, Lawrence WD (2003) Overexpression of p53 is correlated with stromal invasion in extramammary Paget’s disease of the vulva. Hum Pathol 34(9):880–885CrossRefPubMed

Zhou S, Zhong W, Mai R, Zhang G (2017) Mammary and extramammary Paget’s disease presented different expression pattern of steroid hormone receptors. Biomed Res Int 2017:3768247PubMedPubMedCentral

Title: The vulvar immunohistochemical panel (VIP) project: molecular profiles of vulvar Paget’s disease
Authors: Giorgia Garganese
Frediano Inzani
Giulia Mantovani
Angela Santoro
Michele Valente
Gabriele Babini
Giuliana Petruzzellis
Simona Maria Fragomeni
Stefano Gentileschi
Sonia Bove
Massimo Franchi
Giuseppe Angelico
Anna Fagotti
Giovanni Scambia
Gian Franco Zannoni
Publication date: 01-09-2019
Publisher: Springer Berlin Heidelberg
Keyword: Paget's Disease of Bone
Published in: Journal of Cancer Research and Clinical Oncology / Issue 9/2019
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-019-02975-3

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The vulvar immunohistochemical panel (VIP) project: molecular profiles of vulvar Paget’s disease

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2019

Co-expression network analysis identified candidate biomarkers in association with progression and prognosis of breast cancer

A randomized phase II, open-label and multicenter study of combination regimens of bortezomib at two doses by subcutaneous injection for newly diagnosed multiple myeloma patients

Correction to: Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma

A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda

A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis

Selective radiofrequency ablation of tumor by magnetically targeting of multifunctional iron oxide–gold nanohybrid

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page